Shares of Welcure Drugs & Pharmaceuticals hit a 5% upper circuit limit during Monday’s trading session following the company’s announcement that its board will evaluate two significant proposals: a 1:10 stock split of equity shares (transforming one equity share into ten) and the potential issuance of bonus shares at a 1:1 ratio (offering one bonus share for each one held).
These initiatives are intended to enhance the company’s liquidity, broaden its shareholder base, and make shares more accessible to investors. Any approvals will depend on the board’s decision along with the necessary regulatory and shareholder approvals. Information regarding record dates and the schedule for these corporate actions will be provided later, in compliance with SEBI LODR and relevant laws.
